1. Home
  2. ALLO vs LXFR Comparison

ALLO vs LXFR Comparison

Compare ALLO & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • LXFR
  • Stock Information
  • Founded
  • ALLO 2017
  • LXFR 1898
  • Country
  • ALLO United States
  • LXFR United States
  • Employees
  • ALLO N/A
  • LXFR N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • LXFR Major Chemicals
  • Sector
  • ALLO Health Care
  • LXFR Industrials
  • Exchange
  • ALLO Nasdaq
  • LXFR Nasdaq
  • Market Cap
  • ALLO 277.8M
  • LXFR 314.6M
  • IPO Year
  • ALLO 2018
  • LXFR 2012
  • Fundamental
  • Price
  • ALLO $1.21
  • LXFR $12.68
  • Analyst Decision
  • ALLO Strong Buy
  • LXFR
  • Analyst Count
  • ALLO 9
  • LXFR 0
  • Target Price
  • ALLO $8.44
  • LXFR N/A
  • AVG Volume (30 Days)
  • ALLO 2.5M
  • LXFR 120.4K
  • Earning Date
  • ALLO 08-06-2025
  • LXFR 07-29-2025
  • Dividend Yield
  • ALLO N/A
  • LXFR 4.10%
  • EPS Growth
  • ALLO N/A
  • LXFR 49063.50
  • EPS
  • ALLO N/A
  • LXFR 0.79
  • Revenue
  • ALLO N/A
  • LXFR $399,500,000.00
  • Revenue This Year
  • ALLO N/A
  • LXFR $2.63
  • Revenue Next Year
  • ALLO $199.63
  • LXFR $3.30
  • P/E Ratio
  • ALLO N/A
  • LXFR $16.27
  • Revenue Growth
  • ALLO N/A
  • LXFR 1.63
  • 52 Week Low
  • ALLO $0.86
  • LXFR $9.41
  • 52 Week High
  • ALLO $3.78
  • LXFR $15.64
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 43.73
  • LXFR 67.14
  • Support Level
  • ALLO $1.11
  • LXFR $11.89
  • Resistance Level
  • ALLO $1.29
  • LXFR $12.39
  • Average True Range (ATR)
  • ALLO 0.09
  • LXFR 0.31
  • MACD
  • ALLO -0.01
  • LXFR 0.09
  • Stochastic Oscillator
  • ALLO 25.81
  • LXFR 96.82

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.

Share on Social Networks: